Carilion Clinic

Carilion Clinic to partner with The Blood Connection to support blood product needs for local patients ROANOKE, Va., Nov. 15, 2023 /PRNewswire/ -- Carilion Clinic, a not-for-profit integrated health system headquartered in Roanoke, Virginia, has partnered with The Blood Connection (TBC) for its blood product needs. This agreement is effective Dec. 31, 2023. TBC is a non-profit 501(c)(3) community blood center and the primary blood provider for more than 120 hospitals in Virginia, South Carolina, North Carolina, and Georgia. TBC plans to open donation centers locally and will serve our community though hosting mobile blood drives. Expanding into the Roanoke community will allow TBC to increase donor collection opportunities. With this partnership, blood donors can feel confident knowing their donations are helping our community and neighbors. "Carilion is excited about our new blood services partnership with The Blood Connection," said Carilion President and Chief Operating Officer Steve Arner. "TBC is dedicated to supplying our local blood product needs and being involved in the community. We encourage blood donors to support TBC's future blood drives to help them ensure our region has adequate blood to help us care for our patients." "We are honored to partner with Carilion Clinic to provide these lifesaving blood products to local patients," said Delisa English, President and CEO of TBC. "Local blood donors make the difference in sustaining the community blood supply and preventing blood shortages. All blood products used by patients at Carilion will be provided exclusively by TBC. We will immediately begin efforts to collect blood products in the community and are seeking blood donors and organizations who are willing to support this partnership and the local blood supply by sponsoring blood drives." Despite national blood shortages, TBC has continuously proven to be a reliable and dedicated partner for local hospitals – committing itself to ensuring blood products are readily available through volunteer blood donors. TBC adheres to the same high-quality standards as Carilion and is regulated by the FDA and Association for the Advancement of Blood & Biotherapies (AABB). Every two seconds, someone in the U.S. needs a blood transfusion while only three percent of the eligible population donates. 4.5 million Americans will be impacted by a blood donation every year. Surgery patients, accident victims, patients with cancer and newborn babies rely on the local blood supply. Although TBC is responsible for keeping the blood supply stable, it cannot replicate blood; it must be donated. TBC urges the community to donate blood to ensure that hospitals needs are uninterrupted. TBC also encourages and welcomes local schools, businesses, churches, and organizations, to be part of the connection as a blood drive host. To learn more about hosting a blood drive, please visit thebloodconnection.org/host. About The Blood Connection Founded in Greenville, SC, The Blood Connection has been committed to saving lives since 1962. TBC is an independently managed, not-for-profit, community blood center that provides blood products to over 120 hospitals within Virginia, Georgia, South Carolina, and North Carolina. Recognized by the U.S. Congress for its dedication to disaster preparedness and the community, TBC works diligently to collect blood from volunteer donors to meet the ever-increasing demand. By keeping collections local, TBC serves hundreds of thousands of patients a year in its communities. TBC is licensed and regulated by the U.S. Food and Drug Administration. For more information, visit thebloodconnection.org. About Carilion Clinic Carilion Clinic is a not-for-profit health system serving more than one million people in Virginia and West Virginia regions. Headquartered in Roanoke, Carilion's comprehensive network of hospitals, primary and specialty physician practices and other complementary services deliver high-quality, patient-centered care. Carilion's enduring commitment to the health of our communities has advanced over the last decade but remains grounded in providing care to patients regardless of their ability to pay. Beginning with the transformation to the clinic model of a physician-led, integrated healthcare system, Carilion has developed robust academic partnerships with the creation of the Virginia Tech Carilion School of Medicine, the Fralin Biomedical Research Institute at VTC and Radford University Carilion's school for allied health sciences. Carilion advances care through education, research and innovation elements and continues to rely on the generous support of donors to advance its mission to improve the health of the communities we serve. Learn more at CarilionClinic.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube. Contact: Ellen Kirtner, Partnerships & Media Coordinator Phone: (984) 222-1104 Email: [email protected] SOURCE The Blood Connection, Inc.

MELBOURNE, Australia, June 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company's carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx (89Zr-DFO-girentuximab), exploring this potential target across a broad range of cancer indications. The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in patients with a diverse range of solid tumours – including breast, cervix, colorectal, gastric, esophageal, head and neck, lung, ovarian, pancreatic and vulval cancers[2] – for potential diagnostic and therapeutic applications. CAIX is a protein overexpressed on the surface of clear cell renal cell carcinoma (ccRCC), the cancer target in Telix's highly successful Phase III ZIRCON study.[3] It is also expressed to varying degrees in many other advanced-stage solid tumours with poor prognosis. Tumours that express CAIX are typically hypoxic, more aggressive and feature a tumour micro-environment (TME) that can be resistant to therapy, particularly immunotherapies. STARBURST is exploring these tumour types in the refractory setting to assess whether tumour sites can be targeted, both for imaging and potentially therapeutic purpose. The study builds on encouraging preliminary data from two investigator-initiated studies in triple-negative breast cancer and non-muscle-invasive bladder cancer, which demonstrate the potential of TLX250-CDx in these disease settings with unmet medical need. The half-life of 89Zr means that imaging these tumours with TLX250-CDx will enable predictive dosimetry for therapeutic radionuclides, effectively serving as a theranostic "scouting" study for future studies harnessing therapeutic radionuclides. Principal Investigator for the STARBURST study, Dr Jackson Kiser, Medical Director Molecular Imaging at Carilion Clinic in Roanoke, Virginia (U.S.) stated, "CAIX is a cancer target that has now been validated in Telix's Phase III ZIRCON study in ccRCC, and so it is very interesting to explore expanding the potential utility of the same investigational agent in a series of other tumour types known to express this important target." Dr Colin Hayward, Telix Chief Medical Officer, said, "Building on the success of ZIRCON and positive preliminary results in investigator-initiated studies of TLX250-CDx in bladder and breast cancer,[4] dosing a first patient in the STARBURST study is a strategically important milestone for Telix. This study will add value and clinical insight to the platform and enable Telix to assess the potential of CAIX as a biomarker as we continue to scout the theranostic potential of targeting CAIX beyond renal cancer. We would like to thank Dr Kiser and his clinical team at Carilion Clinic, as well as the patients who will contribute to the study." About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). Visit for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on Twitter (@TelixPharma) and LinkedIn. Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[5] and by the Australian Therapeutic Goods Administration (TGA),[6] and by Health Canada.[7] Telix is also progressing a marketing authorisation application for this investigational candidate in the United Kingdom and the European Union.[8] Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: [email protected] Legal Notices This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Except as required by applicable laws or regulations, Telix does not undertake to publicly update or review any forward-looking statements. Past performance cannot be relied on as a guide to future performance. Readers should read this announcement together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. ©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). [1] Positron emission tomography/computed tomography. [2] Literature reports of CAIX expression. [3] Telix ASX disclosure 7 November 2022. [4] Telix ASX disclosure 18 October 2022. [5] Telix ASX disclosure 20 December 2021. [6] Telix ASX disclosure 2 November 2021. [7] Telix ASX disclosure 14 October 2022. [8] Telix ASX disclosure 3 April 2023. Logo - SOURCE Telix Pharmaceuticals Limited

With Converge, Amwell is providing a "unified, fully integrated hybrid care enablement platform, which glues together payers, providers, innovators, and patients," and represents a large unmet need in the market, according to co-CEO Ido Schoenberg. Telehealth giant Amwell saw its losses balloon to nearly $400 million in the first quarter as it was hit with a hefty impairment charge caused by a sustained decline in its share price. The company took a noncash goodwill impairment charge of $330 million as a result of its stock market performance and "associated market capitalization compared to the book value of our equity as of quarter end," Amwell Chief Financial Officer Bob Shepardson told investors and analysts Wednesday during the company's first-quarter 2023 earnings call. Companies opt for impairment when the value of assets or goodwill on their books is no longer fully recoverable.  Amwell (formerly American Well) ended the quarter with $507 million in cash and marketable securities. "We are fortunate to have a substantial cash position as it provides the resources to fund this temporary period of investing and the flexibility to pursue strategic opportunities that are aligned with our goals," Shepardson said.  The company's stock was trading at $2.12 at market close Wednesday, down from a high of $35.54 in October 2020. Amwell's share price dipped nearly 5% in after-hours trading. Telehealth companies have been taking a hit on the stock market, and virtual care companies have seen their market values contract since hitting a high during the peak of the COVID-19 pandemic. As a result of the impairment charge, Amwell posted a net loss for the quarter of $398 million, or a loss of $1.42 per share attributable to common stockholders, basic and diluted, compared to a loss of 26 cents per share a year ago. The company reported an adjusted EBITDA loss of $44.6 million compared to a loss of $47 million during the same period a year ago. Amwell has spent the past year making significant investments in its new virtual care platform, Converge. Converge makes all of Amwell’s products and programs, plus third-party applications, available in one place, like an app store that embeds third-party solutions, according to executives.  The company has been strategically migrating health systems and payer customers over to the new platform. Ido Schoenberg, M.D., co-CEO, called Converge a "unique whole-person one-stop-shop platform that supports the delivery of hybrid healthcare." In the first quarter, Amwell marked go-lives of the Converge platform at Carilion Health, Oluf Medical, Aultman Health and Intermountain Health. "In February, we completed a full system launch with health partners out of Minnesota. This enterprisewide go-live is integrated with Epic and used by clinical teams across many specialties, and health partners' clinicians are already conducting as many as 3,000 visits per day," Schoenberg said. The Boston-based company raked up $138 million in research and development costs in 2022, up 30% compared to 2021, as reported in its full-year 2022 earnings report. Amwell spent $26 million on R&D in the first quarter of this year. Shepardson said the fourth quarter of 2022 represented peak R&D spend, and those investments will decline in the second half of the year. The company is betting big on its Converge platform to help support a digital-first approach to healthcare as virtual care evolves post-pandemic. "In a world where a digital-first approach to hybrid care is a certainty, it's also clear in my discussions with our clients that in the healthcare market, spending always requires rigorous prioritization. Hospital budgets are constrained and the challenges facing providers and payers include widespread technological fragmentation, staffing shortages in an urgent need to improve patient experience and outcomes," Schoenberg told investors Wednesday. "These all drive a demand to evolve to a digital-first model and leveraging technology to achieve operational goals. Despite the inherent challenges our clients and prospects are facing today, we think these investment priorities play right into our strengths. As we take our solution to the market, we are listening carefully, adapting with agility, and driving with urgency," he said. With Converge, Amwell is providing a "unified, fully integrated hybrid care enablement platform, which glues together payers, providers, innovators, and patients," and represents a large unmet need in the market.  Amwell's platform includes automated care programs for maternity ED discharge, chronic disease and pre-colonoscopy, among others, that are proving to have robust clinical and financial outcomes for customers, Schoenberg said. No two clients have the same hybrid care goals, he noted. "Clients are looking to solve the most pressing priorities and the success of their peers provides powerful motivation to act, and increasingly we believe they will choose to partner rather than build a homegrown solution on which to deploy the right hybrid combination of virtual, automated, and in-person care," Amwell's CEO said. The company is now partnering with digital chronic condition management platform DarioHealth to add a cardiometabolic program to its suite of digital offerings. Amwell says it works with about 2,000 hospitals and payers that reach more than 90 million lives. The company brought in $64 million in first-quarter revenue, which was flat compared to a year ago and $15 million lower than last quarter. Revenue missed Wall Street estimates. Analysts expected the company to bring in $65 million in revenue this quarter. "The bulk of this decline was accounted for by lower professional services revenue compared to Q4, which was very busy as we implemented strategic clients onto Converge. Subscription revenue was $28.7 million in Q1, relatively flat compared to the year-ago quarter and down $2 million from last quarter," Shepardson said. The company expects subscription revenue growth in the first half of 2023 to be impacted by the softness in bookings last year as it focuses on its strategic initiatives related to the Converge transition, he noted. The total number of active providers using its virtual care platform grew to around 108,000 during the quarter, up 8% compared to 100,000 a year ago. Amwell saw flat growth in telehealth visits, totaling 1.7 million, the same as last quarter and down from 1.8 million visits a year ago. The company is in the process of migrating its customers over to the new Converge platform. About 36% of the company’s virtual visits occurred through Converge in the first quarter, up from 28% compared to the fourth quarter. During the first quarter, Amwell Medical Group visits grew 9% and AMG revenue grew 6% year over year to reach $32.5 million.  Amwell expects full-year 2023 revenue in the range of $275 million to $285 million and adjusted EBITDA to be in the range of loss of $150 million to a loss of $160 million.